Press release
Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Hereditary Angioedema Pipeline. Dive into DelveInsight's comprehensive report today! @ Hereditary Angioedema Pipeline Outlook [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hereditary Angioedema Pipeline Report
* On 19 August 2025, CSL Behring announced a phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC).
* DelveInsight's Hereditary Angioedema pipeline report depicts a robust space with 20+ active players working to develop 30+ pipeline therapies for Hereditary Angioedema treatment.
* The leading Hereditary Angioedema Companies such as Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
* Promising Hereditary Angioedema Pipeline Therapies such as NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
Stay ahead with the most recent pipeline outlook for Hereditary Angioedema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hereditary Angioedema Treatment Drugs [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hereditary Angioedema Emerging Drugs Profile
* KVD900: KalVista Pharmaceuticals
KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020.Currently the drug is in Phase III stage of development for the treatment of Hereditary angioedema.
* PHA121: Pharvaris
PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase II stage of development.
* BMN 331: BioMarin Pharmaceutical
BMN 331 is a gene therapy product candidate for HAE. It is currently in Phase I stage of development.
The Hereditary Angioedema Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hereditary Angioedema with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema Treatment.
* Hereditary Angioedema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hereditary Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hereditary Angioedema market
Explore groundbreaking therapies and clinical trials in the Hereditary Angioedema Pipeline. Access DelveInsight's detailed report now! @ New Hereditary Angioedema Drugs [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hereditary Angioedema Companies
Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
Hereditary Angioedema Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
Unveil the future of Hereditary Angioedema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hereditary Angioedema Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hereditary Angioedema Pipeline Report
* Coverage- Global
* Hereditary Angioedema Companies- Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
* Hereditary Angioedema Pipeline Therapies- NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
* Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hereditary Angioedema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hereditary Angioedema Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hereditary angioedema: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hereditary angioedema - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Hereditary angioedema Collaboration Deals
* Late Stage Products (Phase III and NDA)
* KVD900: KalVista Pharmaceuticals
* Mid Stage Products (Phase II)
* PHA121: Pharvaris
* Early Stage Products (Phase I)
* BMN 331: BioMarin Pharmaceutical
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Hereditary angioedema Key Companies
* Hereditary angioedema Key Products
* Hereditary angioedema- Unmet Needs
* Hereditary angioedema- Market Drivers and Barriers
* Hereditary angioedema- Future Perspectives and Conclusion
* Hereditary angioedema Analyst Views
* Hereditary angioedema Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hereditary-angioedema-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4158911 • Views: …
More Releases from ABNewswire
Advanced Kidney Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "Advanced Kidney Cancer Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Kidney Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Recurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Tri …
DelveInsight's, "Recurrent or Metastatic Head and Neck cancer Pipeline Insight 2025" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the Recurrent or Metastatic Head and Neck Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent or Metastatic Head and Neck Cancer therapeutics assessment by product type, stage, route of…
Avansaber Launches AI-Powered SAP Utilities ERP to Revolutionize Digital Operati …
How Artificial Intelligence Accelerates SAP Utilities ERP Projects for Smarter Grid Management and Enhanced Customer Experiences
AUSTIN, TX - August 25, 2025 - As the global energy sector navigates the complexities of decarbonization, grid modernization, and rising customer expectations, the role of technology has never been more critical. At the forefront of this transformation is the integration of Artificial Intelligence (AI) into core operational systems. For utility companies leveraging SAP, AI…
Travel Experts Reveal the Only Way to Travel in Luxury to Antarctica
Antarctica remains one of the most remote and pristine destinations on Earth - and now, explorers can discover it in complete luxury.
"I've never met anyone who's returned from Antarctica unchanged," says polar explorer and adventurer Ben Saunders, standing beside a striking image of himself at the South Pole, flashing two thumbs up. "It's truly mind-blowing."
This sentiment is shared by countless travelers who have journeyed to the "white desert." Being surrounded…
More Releases for Hereditary
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
